

# Evaluating the Role of Social Determinants of Health and Patient Demographics on CDK 4/6 Inhibitor Adherence for Breast Cancer



Lena Lebada, PharmD Candidate<sup>1</sup>; Maria Roberts, PharmD<sup>2</sup>; Bethany Boyd, RPh, PhD<sup>3</sup>; Cara Coladonato, PharmD<sup>4</sup>; Angie F Oster, PharmD<sup>5</sup>; Michelle Brisco-Fields, PharmD<sup>6</sup>  
<sup>1</sup>LLUSP- AMCP Foundation/Pfizer, Inc. Oncology Intern, MaxorPlus | <sup>2</sup>MaxorPlus, Director of Specialty Clinical Programs | <sup>3</sup>MaxorPlus, Director of Specialty Clinical Programs | <sup>4</sup>Pfizer, Field Medical Director | <sup>5</sup>MaxorPlus, Clinical Intervention Pharmacist | <sup>6</sup>MaxorPlus, VP of Clinical Strategy and Innovation | <sup>7</sup>VP of Clinical Analytics and Product Development

## BACKGROUND

The impact of social determinants of health (SDOH) and lifestyle risk factors on breast cancer treatment adherence is not well understood. Investigating how socioeconomic status, education, and access to healthcare intersect with specific risk factors can provide crucial insights. This research aims to identify these intersections to enhance targeted interventions and ultimately improve patient outcomes.

A 2023 paper from National Comprehensive Cancer Network<sup>®</sup> (NCCN)<sup>4</sup> showed the significant role of socioeconomic factors in influencing treatment adherence among breast cancer patients. The study highlighted that there should be high impact interventions for patients who have greater needs. The NCCN has developed recommendations for the integration of the highest impact measures into policy and practice. This investigation into the MaxorPlus commercial patient population is aimed to further understand the correlation among SDOH, lifestyle risk factors, and treatment adherence, contributing to the development of more effective, targeted interventions.

## OBJECTIVES

The primary objective is to describe the association of SDOH on breast cancer CDK 4/6 inhibitor treatment adherence in the MaxorPlus commercial patient population.

## METHODS

A retrospective cohort study was conducted on a commercial patient population utilizing CDK 4/6 inhibitors through MaxorPlus. The study period spans from January 2022 to December 2023 focusing on patients who were new to therapy after January 1, 2022.

### Medication criteria:

At least two specialty pharmacy claims for one of the following during the period:

- o Palbociclib (Ibrance<sup>®</sup>)
- o Ribociclib (Kisqali<sup>®</sup>)
- o Ademaciclib (Verzenio<sup>®</sup>)

### Medication adherence assessment:

Medication adherence was assessed using the Proportion of Days Covered (PDC) metric.

- o Index start date was the first fill of their medication in the study period or 180 days prior to the last fill exhaust date
- o Index end date was defined as the last fill of the medication plus 28 days (days supplied)
- o PDC is calculated by the ratio of the number of days the patient is covered by the medication to the number of days the patient is eligible to have the medication on hand
- o PQA provides clinical evidence for a PDC threshold of 80%<sup>3</sup>
- o PDC measurement timeframe was 29 months from January 1, 2022, to May 31, 2024
- o Discontinuation gap was defined as 6 months

### SDOH data:

Definitions of SDOH data:

- o Access to care: Remote area, low population ratio
- o Digital and health literacy: limited health awareness, low education
- o Social isolation: not married, small household size
- o Sedentary lifestyle: limited outdoor or exercise
- o Economic stability: less net worth or low income
- o Transportation: no access to personal vehicle

### Data source

- o Claims data from MaxorPlus book of business
- o SDOH data was accessed using publicly available consumer data

## RESULTS

SDOH data was obtained by compiling public information from databases that are collating factors such as zip code, phone numbers, marriage records, and public data to identify risk factors.

Average age of patient population was 56 years old; average total adherence of total population was 86.8%. Median ages for each medication Ibrance<sup>®</sup> (60 years), Verzenio<sup>®</sup> (52 years), and Kisqali<sup>®</sup> (58 years).

Age range:	
<55	63
55-65	54
>65	26
Medication type:	
Kisqali <sup>®</sup>	26
Ibrance <sup>®</sup>	40
Verzenio <sup>®</sup>	77
Gender:	
Female	141
Male	2
SDOH risk factors groups:	
0	19
1	28
2	45
3	51
Median medication adherence:	
Kisqali <sup>®</sup>	89%
Ibrance <sup>®</sup>	89%
Verzenio <sup>®</sup>	93%

### Breast cancer population identification, Table 1:


143 patients met inclusion criteria and were on CDK 4/6 inhibitors. Majority of members were 56 years old and had pharmacy claims.

\*No one triggered for transportation as a risk factor

Adherence level	Patient count	Access to care	Digital and health literacy	Social isolation	Sedentary lifestyle	Economic stability
≥90%	75	11 (14.67%)	12 (16%)	27 (36.00%)	28 (37.33%)	34 (45.33%)
80-89%	36	5 (13.89%)	7 (19.44%)	14 (38.89%)	11 (30.56%)	18 (47.22%)
<80%	32	4 (12.50%)	13 (40.63%)	12 (37.50%)	12 (37.50%)	8 (25.00%)

### SDOH and adherence distribution, Table 2:

Digital and health literacy showed the greatest increase in the <80% patient population for attributing to poor adherence.



### Age distribution by adherence level Figure 1:

Majority of patients <65 years old, shown in figure 1, have an adherence level of less than 80%. As the patient demographic ages, the adherence levels decrease.

Adherence level	Number of SDOH factors			
	0	1	2	3
≥90%	13.33%	22.67%	29.33%	34.67%
80-89%	11.11%	13.89%	41.67%	33.33%
<80%	15.63%	18.75%	25.00%	40.63%

### % Patients by number of SDOH factors, Table 3:

Patients with a greater amount of SDOH factors were consistently less adherent.

## CONCLUSIONS

Forty percent of the members in the <80% cohort were at risk for having a digital or health literacy-related SDOH factor, indicating this may contribute to poor adherence.

Developing educational resources and targeted outreach may increase patients' adherence levels.

MaxorPlus Specialty Pharmacy Clinical Programs can be developed to provide further outreach to ensure patients receive proper education on CDK 4/6 treatment.

These findings can help generate future studies to develop targeted strategies to improve adherence in breast cancer patients.

Further investigations are necessary to assess the significance of these results and understand their impact.

Pharmacy benefit managers or specialty pharmacies can incorporate these findings by implementing comprehensive patient education programs that ensure personalized support and follow-up to improve adherence rates.

## LIMITATIONS

- o This study does not include medical claims data, limiting its comprehensiveness
- o The PDC metric cannot account for missed medications due to neutropenia or side effects
- o Patients may have additional insurance coverage, such as Medicare
- o The small patient population size overtakes robust statistical analysis

## ACKNOWLEDGEMENTS

Thank you to Pfizer, Inc. for funding the AMCP Foundation Oncology Internship Program

1. MaxorPlus, Pfizer Insights Historical Utilization Data, Commercial Segment, Year to Date 2022 versus 2023, 2024  
 2. MaxorPlus, Pfizer Insights Historical Utilization Data, Managed Care Case Study, January 2024  
 3. PQA, Patient Questionnaire, Pfizer Clinical Oncology, Commercial Segment, Pfizer, Chicago, IL, July 2023  
 4. National Comprehensive Cancer Network (NCCN), Managing And Addressing Health-Related Social Needs In Cancer, Version 2.02023, Accessed at 05/01/2024 (https://www.nccn.org/docs/other/pdf/2023\_nccn\_hrsn.pdf)